|
Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors. |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
Research Funding - AstraZeneca (Inst); Roche (Inst) |
| |
|
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Bristol-Myers Squibb; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Janssen; MAB Discovery; NeoMed; Roche; Seagen; Thermo Fisher Scientific |
Speakers' Bureau - Lilly; MSD; Novartis; Roche; Thermo Fisher Scientific |
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst) |
Other Relationship - Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); BioNTech (Inst); Catalym (Inst); CytomX Therapeutics (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Ribon Therapeutics (Inst); Roche (Inst); Seagen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst) |
| |
|
Employment - BioCytics; Carolina BioOncology Institute |
Leadership - BioCytics; Carolina BioOncology Institute |
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute |
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc |
Research Funding - Abbvie; Adagene (Inst); Alkermes; Apros Therapeutics; Arcus Biosciences; Ascendis Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals; Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; I-Mab (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); Molecular Templates (Inst); MT Group (Inst); NextCure (Inst); Nuvation Bio (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst) |
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy |
| |
|
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncorus (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Turning Point Therapeutics (Inst); WindMIL (Inst) |
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst) |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi |
| |
|
Honoraria - Bms spain; Roche |
Consulting or Advisory Role - BeiGene |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bms Spain; MSD; Roche; Roche |
| |
|
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Janssen Oncology; Janssen Oncology; Sanofi |
Research Funding - Sanofi |
| |
|
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Lilly; Novartis |
Expert Testimony - Novartis |
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; Novartis; Roche |
| |
|
Employment - MD Anderson Cancer Center |
Consulting or Advisory Role - Abbvie; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Kolon Life Sciences; Lengo Therapeutics; Loxo; OnCusp Therapeutics; PACT Pharma; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Tyra Biosciences; Xencor; Zentalis; Zymeworks |
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst) |
| |
Cesar Augusto Santa-Maria |
Consulting or Advisory Role - Athenex |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Pfizer; Tesaro/GSK |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
Other Relationship - Akoya Biosciences |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Genentech; Ipsen; Janssen; Lilly; MedImmune; Merck Sharp & Dohme; Novartis; Orion; Pfizer; Roche; Sanofi |
Other Relationship - Abbvie; Aduro Biotech; Agios; Amgen; Argenx; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; Forma Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; Gortec; H3 Biomedicine; Incyte; Innate Pharma; ITeos Therapeutics; Janssen; Kura Oncology; Kyowa Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merus; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Oncopeptides; Orion; Pfizer; PharmaMar; Pierre Fabre; Roche; Sanofi; Servier; Sierra Oncology; Taiho Pharmaceutical; Takeda; Tesaro; The Lymphoma Academic Research Organization; Xencor |
| |
|
Leadership - Treadwell Therapeutics (I) |
Stock and Other Ownership Interests - Agios (I) |
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics |
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst) |